🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The DAR-UM-2 trial now has its first UK site open! The trial, run by IDEAYA Biosciences, is looking at a new treatment combination for metastatic uveal melanoma. Have a look at our Melanoma TrialFinder to find more information. 🔎 More UK sites are planned to open soon!

There will be an incredible session on uveal melanoma! Make sure to register to be a part of the conversation - buff.ly/46GiBby

📢 ASM Program available! ✅2 keynote speakers ✅17 melanoma and skin cancer clinical trial experts ✅6 consumers with unique perspectives on clinical trials. Visit the MASC Trials ASM website for program & speaker info. Register ASAP - seats are limited! masc.org.au/asm-2024/

Know someone in healthcare about to dip their toe into using social media professionally? I created a (helpful, I think!) guide to using social media successfully, safely, and ethically. Download it for free: glaucomflecken.com/med-social-med…

A truly groundbreaking trial, now presenting minimum of 10 year data, showing a “descriptively better” survival for ipi/nivo #ESMO24

Happy to share the final version of our eLife - the journal manuscript on tumor-reactive lymphocytes (TRLs) in uveal melanoma elifesciences.org/articles/91705 By using single cell seq and a live biobank of TILs & patient-derived mice (xenografts) we tease out the molecular characteristics of TRLs! ->

I was bullied at my last workplace, and I have since reported it to WH&S. Thanks to the world we live in, technology lets bullying continue to snowball. This post isn't a cry for help. It is me letting the world know bullying happens to innocent adults as well.

We’re hosting a series of Policy Roundtables with Australian Genomics. We sat down for a behind-the-scenes chat ahead of the first session in Canberra last month: bit.ly/3A65zrF

I had noticed King Charles had a nice pair of dark sunnies on at his events in Sydney. 😃 To hear #slipslopslapseekslide was mentioned to him made me smile 😁 (and made me feel old, I was diagnosed 2yrs before seek and slide were added to the campaign in 2007) 😎

Off topic to my regular posts, Simone is connected to my daughters workplace, he and Viviana have my full support 👏

New Research Involved Nearly 2400 Patients Proves the Efficacy and Safety of #Cyberknife Radiotherapy to Treat Uveal Melanoma, Also Known as #OcularMelanoma. For more info call #CyberKnifeMiami 305-279-2900 #cancertreatmentinmiami tinyurl.com/mryzatun

What if targeting TP53 mutations, once thought “undruggable,” could become a therapeutic reality? The PYNNACLE phase 1/2 study presented at #SABCS2024 is shedding new light on this possibility. Prof. Penault-Llorca and Dr. Dumbrava share their expert insights on rezatapopt, an

Thank you to Dr Louise Nott, Profs Anthony Joshua and Mark Shackleton, and Tasmanian attendees for joining the MASC Trials team at the AOMA Hobart meeting at Crowne Plaza Hobart on Friday evening. Many thanks to Medison for sponsoring this event! #MASCTrials #Medison

🎉Entries are open for the 2025 Australian Museum Australian Museum Eureka Prizes! Do you know an outstanding scientist, innovator or science communicator? Encourage them to get their achievements recognised. Enter or nominate now at australian.museum/eureka #EurekaPrizes

RSVP now for our "Together Against Melanoma Patient & Caregiver Symposium" held in collaboration with UNC Lineberger Comprehensive Cancer Center. This is an opportunity to learn and connect with others who are navigating the #melanoma journey. Join us: buff.ly/3EBUArX

Now online in Cancer Discovery: Restoration of the Tumor Suppressor Function of Y220C-Mutant #p53 by Rezatapopt, a Small Molecule Reactivator - by Anna Puzio-Kuter, Lizhong Xu, Masha Poyurovsky, and colleagues doi.org/10.1158/2159-8… pmvpharma

Exiting day for cancer patient advocacy in Ireland with the launch of UCAN Ireland. #WeAreUCAN #UnitedCancerVoicesIE #StrongPatientVoice #FairAccessNow